In 2025, an estimated 16,800 women in Latin America and the Caribbean died from ovarian cancer, according to the Global Cancer Observatory. In Panama, the most recent figures record 69 deaths from ovarian cancer. Dr. David Gómez, Uro-oncology Manager for Adium Central America and the Caribbean, emphasizes that unlike other cancers, ovarian cancer lacks a universal screening test for early detection, which hinders timely diagnosis as the disease often presents no specific symptoms in its early stages. Specialists note that global projections indicate a 55% increase in new cases by 2050, posing significant challenges to healthcare systems, particularly in improving detection and treatment methods. Early detection could impact cure rates. While science advances in finding early detection tests, it is crucial to be aware of risk factors, such as hereditary and genetic mutations, age, and reproductive factors. Medicine has made valuable advances in targeted therapies and immunotherapy for ovarian cancer patients, improving survival rates. However, research shows that only one in four women had heard of ovarian cancer and had some knowledge of it before being diagnosed. The average time from symptom onset to accessing treatment is between 3 and 11 months in some countries. A key focus is the development of early detection strategies and personalized treatments, ensuring integrated oncological care.
